AbbVie (ABBV) Receives a Buy from Scotiabank
Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie (ABBV) with a $280 price target. AbbVie reported Q2 revenue of $16.99B and net profit of $3.61B, up from last year's $15.42B revenue and $938M profit. Insider sentiment is negative, with recent sales by executives.
How this was made
The 30-second read
Why it matters
The new Buy rating and $280 target suggest upside potential, but insider selling may introduce downside risk.
Market read
Analyst upgrades can move the stock in the short term; combined with strong earnings, AbbVie may see modest buying pressure.
What to watch
Recent insider sell-offs and mixed analyst opinions (Citi Hold) may temper the upside.
Background
AbbVie reported Q2 earnings with revenue of $16.99 bn and net profit of $3.61 bn, up from the prior year.
Ticker impact
Scotiabank analyst Louise Chen upgraded AbbVie to Buy and set a $280 price target, while RBC also issued a Buy and Citi maintained Hold.
likely upward pressure as investors price in the new target
The upgrade is a fresh, primary disclosure and includes a concrete price target, which typically prompts buying interest.
Market effects
May reinforce positive sentiment for the broader healthcare sector as analysts show confidence in large pharma earnings.
U.S. market focus; limited regional effect.
Minor global impact, primarily relevant to U.S. investors.
Counterpoint
The upgrade could be premature if the recent insider selling signals underlying concerns.
Key entities
- Analyst FirmScotiabank
Issued a Buy rating and $280 price target for AbbVie.
- Analyst FirmRBC Capital
Also issued a Buy rating for AbbVie.
- Analyst FirmCiti
Maintained a Hold rating on AbbVie.
